American Renal Associates Holdings, Inc. (ARA) 10-Q Quarterly Report November 2017

BEVERLY, MA (November 14, 2017) - American Renal Associates Holdings, Inc. (NYSE: ARA) (“ARA” or the “Company”), a leading provider of outpatient dialysis services, today announced financial and operating results for the third quarter ended September 30, 2017.

Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures (See “Use of Non-GAAP Financial Measures” and the reconciliation tables further below).

Third Quarter 2017 Highlights (all percentage changes compare Q3 2017 to Q3 2016 unless noted):


•	Net patient service operating revenues decreased 2.7% to $187.7 million;


•	Net income attributable to American Renal Associates Holdings, Inc. was $8.0 million as compared to $12.4 million in Q3 2016;


•	Adjusted EBITDA less noncontrolling interests (“Adjusted EBITDA-NCI”) was $28.1 million as compared to $32.5 million in Q3 2016;


•	Adjusted net income attributable to American Renal Associates Holdings, Inc. was $6.4 million, or $0.19 per share, for Q3 2017;


•	Total dialysis treatments increased 6.8%, all of which was non-acquired growth. The Company estimates that operational disruptions related to Hurricanes Harvey and Irma unfavorably impacted Q3 2017 treatment growth by approximately 0.4%; and


•	As of September 30, 2017, the Company operated 217 outpatient dialysis centers serving approximately 15,200 patients.

Joseph (Joe) Carlucci, Chairman and Chief Executive Officer, said, “We are very pleased with our third quarter 2017 results. During the third quarter of 2017, our organization maintained its strong focus on delivering high quality patient care, while also sustaining its performance on the operational initiatives we outlined earlier this year. Our third quarter results further demonstrate that these operating initiatives firmly position our organization in a manner that should allow us to maintain a more efficient cost structure going forward.”

“During the third quarter of 2017, we opened one new de novo clinic, sold one clinic and ended the period with a pipeline of 36 signed clinics at September 30, 2017. Our business development pipeline continues to be strong and reflects the growing acceptance of our operating philosophy and the physician partnership model within the nephrology community,” continued Carlucci.

The following information was filed by American Renal Associates Holdings, Inc. (ARA) on Tuesday, November 14, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1498068/000149806817000085/ara-9302017x10q.htm

View differences made from one quarter to another to evaluate American Renal Associates Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by American Renal Associates Holdings, Inc..

Continue

Assess how American Renal Associates Holdings, Inc.'s management team is paid from their Annual Proxy

American Renal Associates Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

American Renal Associates Holdings, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract

Exhibit 10.2: Material Contract

Exhibit 10.3: Material Contract

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ARA
CIK: 1498068
Form Type: 10-Q Quarterly Report
Accession Number: 0001498068-17-000085
Submitted to the SEC: Tue Nov 14 2017 5:13:36 PM EST
Accepted by the SEC: Tue Nov 14 2017
Period: Saturday, September 30, 2017
Industry: Health And Allied

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/ara/0001498068-17-000085.htm

American Renal Associates Holdings, Inc. (ARA) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

SEC Filings

ARA Valuations

ARA Annual Reports

ARA Quarterly Reports

ARA Corporate News